Antibacterial Agents TRIZ Cases

PTM compositions merge polyphenols, metal ions, and clinical drugs to overcome drug resistance while maintaining microbiome selectivity.

Structural modifications enhance water solubility and bioavailability to treat multi-drug resistant tuberculosis.

Phthalazine compounds modulate kinase activity to treat inflammatory disorders while improving specificity over prior therapies.

A mucolytic agent reduces mucus viscosity to allow antibiotics to penetrate the protective barrier and target pathogens effectively.

Segmented binding site design targets the RAF kinase activation loop pocket to inhibit mutated BRAF signaling pathways.

A photosensitizer composition combined with low-concentration EDTA enables targeted photoablation of microorganisms.

Diaminopyridine compounds inhibit PTK2 to induce apoptotic cell death, resolving the trade-off between broad anti-cancer activity and specific kinase targeting.

A beta-galactoside self-immolative linker selectively cleaves to release active agents within target cells.

Alkaline EDTA compositions mitigate microbial biofilms and reduce drug-resistant organism risks during topical infection therapy.

Benzimidazole derivatives block MvfR signaling to suppress antibiotic tolerance and prevent resistant strain formation in Gram-negative infections.

H-phosphonate intermediate enables efficient triphosphate oligonucleotide synthesis using diphenyl phosphite and pyrophosphate reagents.

Segmenting Quillaja saponin into separate ISCOM particles reduces toxicity while maintaining immunogenicity.

Cationic ionene compositions electrostatically disrupt bacterial membranes, resolving resistance development in Mycobacterium tuberculosis treatment.

Citrus extracts replace toxic chemicals to synthesize tellurium nanoparticles, overcoming antibiotic resistance.

Chemical modification of teicoplanin extends serum half-life, enabling once-weekly dosing for severe bacterial infections.

Removing lipopolysaccharide from Acinetobacter baumannii cells reduces endotoxin toxicity while maintaining robust immunogenicity for safe human use.

Small molecule compounds of Formula I replace antibody injections with oral administration, improving stability and bioavailability while reducing toxicity.

Pyridine derivatives target mycobacterial ATP synthase to shorten treatment duration and reduce toxicity from toxic second-line drugs.

Gradient cooling of erythromycin in dichloromethane reduces impurities and boosts microbiological titre.

Composite particles with hydrophobic cores and charged surfaces resolve toxicity issues while maintaining chemical stability.

Combining low and high molecular weight hyaluronic acids resolves the trade-off between rapid surface coverage and sustained therapeutic duration.

Segmented affinity purification and parameter-changed buffers reduce host cell protein content below 100 ppm while preventing particle formation.

R-107 prodrug eliminates toxic solvents by converting to active R-100 upon plasma exposure.

Heterocyclic modifications on oxazolidinone cores expand antibacterial spectrum against resistant pathogens while lowering human toxicity.

Novel dihydroorotate dehydrogenase inhibitors overcome side effects by optimizing molecular structures for selective enzyme binding.

Thirteen polysaccharide-protein conjugates induce elevated serum IgG titers to address serotype replacement in infants.

Hydrophilic groups reduce eukaryotic cell membrane penetration while the compound suppresses metallo-beta-lactamase activity to restore carbapenem efficacy.

Novel heteroaryl compounds inhibit specific signal enzymes to treat diseases characterized by excessive cell proliferation.

Targets Clostridium difficile infection and opioid-mediated motility inhibition using combined anti-clostridial and opioid blocking agents.

Pyrazolylbenzene-1,3-diols address the lack of selective synthetic ligands by providing compounds with dual activity on GPR18 and TRPV1 receptors.

Malic acid salt derivatives of quinolone antibiotics overcome bacterial resistance mechanisms while maintaining therapeutic efficacy against MRSA strains.

Intradermal inactivated Lawsonia vaccine breaks through maternally derived antibodies to protect pigs against proliferative enteropathy.

Helium pre-implantation forms an amorphous layer stopping dopants at the interface, preventing channeling and residual damage.

Kinase inhibitors target host cell proteins to block pathogen-host interactions, preventing resistance development while minimizing host toxicity.

A stable quaternary ammonium complex merges carvacrol and lidocaine into a single molecular entity.

Specific bacteria and enzymes produce secondary bile acids that reduce pathogenic infection risk.

A chlorine dioxide bleaching composition with a thickener component delivers rapid tooth whitening.

An enteric-coated capsule releases N-methylol transfer agents at pH 5.4 to 6.5 in the duodenum.

Fructus Schisandrae extracts protect against cardiovascular, hepatic, and renal damage induced by chemotherapy drugs.

In situ generation of fusidic acid from sodium fusidate under inert gas purging creates a stable medicinal cream.

Methyl jasmonate and chitin stimulate Tripterygium wilfordii cells to produce 22 times more Celastrol than standard culture methods.

Solid-phase capture isolates intact IgG to enrich supernatant fragments, resolving detection precision limits while peptides restore lost effector functions.

Human beta defensin 2 reduces TNF-alpha activity and inflammation by downregulating pro-inflammatory cytokines.

Isolated monoclonal antibodies targeting human CD27 modulate T cell responses through specific CDR sequences.

Attenuated Streptococcus pneumoniae pep27 mutant induces immune tolerance to prevent inflammatory diseases without adjuvants.

Adsorbent polymer capsule walls absorb moisture to prevent humidity-induced stickiness and ensure reliable fine particle delivery.

Fenretinide normalizes the DHA to arachidonic acid ratio, correcting lipid imbalances that drive lung inflammation in cystic fibrosis.

Functionalizing agents coat copper(I) halide nanoparticles to maintain suspension stability and prevent aggregation in carrier solutions.